The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions

J Clin Invest. 2023 Oct 2;133(19):e173156. doi: 10.1172/JCI173156.

Abstract

First achieved in 1998 by Cole et al., the complete genome sequence of Mycobacterium tuberculosis continues to provide an invaluable resource to understand tuberculosis (TB), the leading cause of global infectious disease mortality. At the 25-year anniversary of this accomplishment, we describe how insights gleaned from the M. tuberculosis genome have led to vital tools for TB research, epidemiology, and clinical practice. The increasing accessibility of whole-genome sequencing across research and clinical settings has improved our ability to predict antibacterial susceptibility, to track epidemics at the level of individual outbreaks and wider historical trends, to query the efficacy of the bacille Calmette-Guérin (BCG) vaccine, and to uncover targets for novel antitubercular therapeutics. Likewise, we discuss several recent efforts to extract further discoveries from this powerful resource.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antitubercular Agents
  • BCG Vaccine
  • Humans
  • Mycobacterium tuberculosis* / genetics
  • Tuberculosis* / prevention & control

Substances

  • BCG Vaccine
  • Antitubercular Agents